Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1111 Main St Ste 660 VANCOUVER WA 98660-2970 |
Tel: | N/A |
Website: | https://www.cytodyn.com |
IR: | See website |
Key People | ||
Jacob P. Lalezari Chief Executive Officer | Mitchell Cohen Interim Chief Financial Officer | Max Lataillade Senior Vice President and Head of Clinical Development | Tyler Blok Corporate Secretary, Chief Legal Officer |
Business Overview |
CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells. It has studied leronlimab in multiple therapeutic areas, including infectious disease, oncology, and autoimmune conditions. The Company has conducted clinical trials of leronlimab as a viral entry inhibitor for human immunodeficiency virus (HIV), believed to competitively bind to the N-terminus and second extracellular loop of the CCR5 receptor. For immunology, the CCR5 receptor is believed to be implicated in immune-mediated illnesses such as Metabolic dysfunction-associated steatohepatitis. It has a joint development agreement with a third-party generative artificial intelligence (AI) drug discovery and development company to develop one or more longer-acting molecules. |
Financial Overview |
For the three months ended 31 August 2024, CytoDyn Inc revenues was not reported. Net income applicable to common stockholders totaled $18.9M vs. loss of $11.9M. Net income reflects Finance charges decrease of 98% to $14K (expense), loss on induced conversion decrease of 41% to $1.2M (expense), General and administrative - Balancing decrease of 32% to $1M (expense). |
Employees: | 9 as of Aug 15, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $153.74M as of Aug 31, 2024 |
Annual revenue (TTM): | $0.00M as of Aug 31, 2024 |
EBITDA (TTM): | $9.02M as of Aug 31, 2024 |
Net annual income (TTM): | -$20.53M as of Aug 31, 2024 |
Free cash flow (TTM): | -$1.05M as of Aug 31, 2024 |
Net Debt Last Fiscal Year: | $4.00M as of Aug 31, 2024 |
Shares outstanding: | 1,219,841,932 as of Sep 15, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |